Loading…
Loading…
TRCK does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TRCK and 80,000+ other tickers.
See exactly how TRCK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TRCK and 80,000+ other tickers.
Track Group, Inc., along with its subsidiaries, specializes in the development, production, and global distribution of advanced location tracking devices. Its diverse product portfolio encompasses hardware solutions like the ReliAlert XC4, a GPS monitoring device, and the ReliAlert XC3, which not only tracks offender movements but also facilitates real-time two/three-way voice communication directly with individuals. Another key device is Shadow, an offender tracking unit compliant with 3G technology. Beyond hardware, the company delivers a suite of software and services. These include…
Dick's Sporting Goods (NYSE:DKS) is plunging 25.3% to trade at $134.03, after the sporting-goods retailer's fiscal second-quarter earnings and revenue fell short of Wall Street's targets.
VGMS is a diversified bond ETF, focusing on corporate bonds. The portfolio is roughly evenly divided between investment and non-investment grade, leaning short-term, with a duration of 3.7 years. Unlike most Vanguard funds, VGMS is active. It could and has outperformed its benchmark since inception, only since last year.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanf.
FIX's record backlog, technology demand and Modular expansion support strong growth, but tougher comparisons may slow momentum.
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA study enrollment underway NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant selective inhibitor of mutant IDH1. "People with IDH1-mutant glioma urgently need additional treatment options.